The extent of HLA-DR expression on HLA-DR+ Tregs allows the identification of patients with clinically relevant borderline rejection

Transplant International

Volumn 26, Issue 3, 2013, Pages 290-299

  Schaier, Matthias ^a   Seissler, Nicole ^a   Becker, Luis Eduardo ^a   Schaefer, Sebastian Markus ^a   Schmitt, Edgar ^b   Meuer, Stefan ^a   Hug, Friederike ^a   Sommerer, Claudia ^a   Waldherr, Rüdiger ^a   Zeier, Martin ^a   Steinborn, Andrea ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

borderline rejection; non invasive marker; renal transplantation; Tregs

Indexed keywords

CYCLOSPORIN A; HLA DR ANTIGEN; MYCOPHENOLIC ACID; STEROID; TACROLIMUS;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GRAFT REJECTION; HLA-DR ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LINEAR MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874118011     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12032     Document Type: Article

References (36)

1. Josephson MA,. Monitoring and managing graft health in the kidney transplant recipient. Clin J Am Soc Nephrol 2011; 6: 1774.
2. Sis B, Mengel M, Haas M, et al,. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464.
3. Racusen LC, Solez K, Colvin RB, et al,. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
4. Kirk AD, Jacobson LM, Heisey DM, Radke NF, Pirsch JD, Sollinger HW,. Clinically stable human renal allografts contain histological and RNA-based findings that correlate with deteriorating graft function. Transplantation 1999; 68: 1578.
5. Thierry A, Thervet E, Vuiblet V, et al,. Long-term impact of subclinical inflammation diagnosed by protocol biopsy one year after renal transplantation. Am J Transplant 2011; 11: 2153.
6. Beimler J, Zeier M,. Borderline rejection after renal transplantation-to treat or not to treat. Clin Transplant 2009; 23 (Suppl 21): 19.
7. Choi BS, Shin MJ, Shin SJ, et al,. Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten-year experience at a single center. Am J Transplant 2005; 5: 1354.
8. Miyagi M, Ishikawa Y, Mizuiri S, Aikawa A, Ohara T, Hasegawa A,. Significance of subclinical rejection in early renal allograft biopsies for chronic allograft dysfunction. Clin Transplant 2005; 19: 456.
9. Heilman RL, Devarapalli Y, Chakkera HA, et al,. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant 2010; 10: 563.
10. Nemeth D, Ovens J, Opelz G, et al,. Does borderline kidney allograft rejection always require treatment? Transplantation 2010; 90: 427.
11. + T reg cells. J Exp Med 2006; 203: 1701.
12. Banham AH, Powrie FM, Suri-Payer E,. FOXP3 + regulatory T cells: Current controversies and future perspectives. Eur J Immunol 2006; 36: 2832.
13. Vondran FW, Timrott K, Tross J, et al,. Association of high anti-donor alloreactivity and low frequency of FoxP3-expressing cells prior to kidney transplantation with acute graft rejection. Clin Transplant 2010; 25: 905.
14. Muthukumar T, Dadhania D, Ding R, et al,. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 2342.
15. + regulatory T-cells in renal allografts: correlation with long-term graft function and acute rejection. Clin Nephrol 2011; 75: 91.
16. Batsford S, Dickenmann M, Durmuller U, Hopfer H, Gudat F, Mihatsch M,. Is monitoring of FOXP3 Treg cells in renal transplants during acute cellular rejection episodes useful? Clin Nephrol 2011; 75: 101.
17. Boros P, Bromberg JS,. Human FOXP3 + regulatory T cells in transplantation. Am J Transplant 2009; 9: 1719.
18. Baecher-Allan C, Wolf E, Hafler DA,. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 2006; 176: 4622.
19. Ashley CW, Baecher-Allan C,. Cutting Edge: responder T cells regulate human DR+ effector regulatory T cell activity via granzyme B. J Immunol 2009; 183: 4843.
20. Sis B, Jhangri GS, Riopel J, et al,. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168.
21. Schaier M, Seissler N, Schmitt E, et al,. DR(high+)CD45RA(-)-Tregs Potentially Affect the Suppressive Activity of the Total Treg Pool in Renal Transplant Patients. PLoS ONE 2012; 7: e34208.
22. Kisielewicz A, Schaier M, Schmitt E, et al,. A distinct subset of HLA-DR+-regulatory T cells is involved in the induction of preterm labour during pregnancy and in the induction of organ rejection after transplantation. Clin Immunol 2010; 137: 209.
23. de Freitas DG, Sellares J, Mengel M, et al,. The Nature of Biopsies with "Borderline Rejection" and Prospects for Eliminating This Category. Am J Transplant 2012; 12: 191.
24. Solez K, Axelsen RA, Benediktsson H, et al,. International standardization of criteria for the histological diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
25. Schaier M, Vorwalder S, Sommerer C, et al,. Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats. Am J Physiol Renal Physiol 2009; 297: F769.
26. Ricardo SD, van Goor H, Eddy AA,. Macrophage diversity in renal injury and repair. J Clin Invest 2008; 118: 3522.
27. Wang Y, Wang YP, Zheng G, et al,. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int 2007; 72: 290.
28. Walsh PT, Taylor DK, Turka LA,. Tregs and transplantation tolerance. J Clin Invest 2004; 114: 1398.
29. Jiang S, Lechler RI,. Regulatory T cells in the control of transplantation tolerance and autoimmunity. Am J Transplant 2003; 3: 516.
30. Sakaguchi S, Ono M, Setoguchi R, et al,. Foxp3 + CD25 + CD4 + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 8.
31. Ashton-Chess J, Dugast E, Colvin RB, et al,. Regulatory, effector, and cytotoxic T cell profiles in long-term kidney transplant patients. J Am Soc Nephrol 2009; 20: 1113.
32. Dijke IE, Korevaar SS, Caliskan K, et al,. Inadequate immune regulatory function of CD4 + CD25bright+FoxP3 + T cells in heart transplant patients who experience acute cellular rejection. Transplantation 2009; 87: 1191.
33. Steinborn A, Schmitt E, Kisielewicz A, et al,. Pregnancy-associated diseases are characterized by the composition of the systemic regulatory T cell (T(reg)) pool with distinct subsets of T(regs). Clin Exp Immunol 2012; 167: 84.
34. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B,. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
35. Ekberg H, Bernasconi C, Tedesco-Silva H, et al,. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876.
36. Baecher-Allan CM, Costantino CM, Cvetanovich GL, et al,. CD2 costimulation reveals defective activity by human CD4 + CD25 hi regulatory cells in patients with multiple sclerosis. J Immunol 2011; 186: 3317.